However, combining BT with PD-1 inhibitors significantly improved survival and prevented the outgrowth of CD24+ tumor cells, which are resistant to conventional therapies and escape immune clearance via SIGLEC-10-mediated macrophage suppression.19,54 These results emphasize the potential of combining RBP inhibition with ICT to reprogram immune-desert tumors. The gene discussed is PDCD1; the disease is neoplasm.